In breast cancer cells, melittin was shown to suppress the EGF-induced cell motility (EGF: epidermal growth factor) and invasion by inhibiting the PI3K/Akt/mTOR (PI3K: phosphatidylinositol-3-kinase, Akt: protein kinase B, mTOR: mammalian target of rapamycin) signalling pathway [19]. Here, AKT1 is linked to breast carcinoma.